The PFA-SHAM trial and MANIFEST-US registry support the efficacy and safety of the increasingly used ablation modality.
Autonomix's targeted ablation therapy improved symptoms, functionality, and quality of life in severe pancreatic cancer patients, especially those with stage 4 disease. Rapid pain relief and durable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback